CancerDrs

Colorectal Cancer clinical trials in Utah

32 actively recruiting colorectal cancer trials at 4 sites across Utah.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Utah:
  • Local Institution - 0426 — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Utah:
  • Community Cancer Trials of Utah ( Site 0086) — Ogden, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Utah:
  • Utah Cancer Specialists — Salt Lake City, Utah
  • University of Utah Health Huntsman Cancer Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …

Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…

Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Utah:
  • START Center for Cancer Care - Mountain Region — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after the…

Sponsor: NSABP Foundation Inc
NCT ID: NCT07058012
Sites in Utah:
  • Huntsman Cancer Institute - University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-human Study of 7MW4911 in GI Cancer

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
NCT ID: NCT07216560
Sites in Utah:
  • START Moutain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07223047
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…

Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06131840
Sites in Utah:
  • START Mountain Region — Salt Lake City, Utah
  • South Texas Accelerated Research Therapeutics Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
  • START Mountain Region, LLC. — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06917079
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, a…

Sponsor: Vividion Therapeutics, Inc.
NCT ID: NCT06004245
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor typ…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07503808
Sites in Utah:
  • START Mountain Region, LLC — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…

Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study als…

Sponsor: Pfizer
NCT ID: NCT07318805
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →

Showing 25 of 32 trials with sites in Utah. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01